<DOC>
	<DOCNO>NCT00045760</DOCNO>
	<brief_summary>Severe sepsis define systemic inflammatory response syndrome result infection associate acute organ dysfunction . It usually result bacterial infection , may occur response pathogen , fungi , virus , parasite .</brief_summary>
	<brief_title>The Study Drotrecogin Alfa ( Activated ) Subpopulation Adult Patients With Severe Sepsis</brief_title>
	<detailed_description>Drotrecogin alfa ( activate ) , recombinant form human activate protein C , first therapeutic intervention show reduce all-cause mortality severe sepsis . In Phase 3 study ( F1K-MC-EVAD ; PROWESS ) , 1690 patient randomly assign receive 96-hour intravenous infusion drotrecogin alfa ( activate ) 24 micrograms/kg/h placebo ( 850 patient 840 patient , respectively ) . Overall , administration drotrecogin alfa ( activate ) yield clinically significant reduction 28-day all-cause mortality : 24.7 % drotrecogin alfa ( activate ) patient die versus 30.8 % placebo patient ( 19.4 % relative risk reduction ; p=0.005 ; Bernard et al . 2001 ) . The safety concern note Phase 3 trial increase risk serious bleeding among drotrecogin alfa ( activate ) patient ( 3.5 % versus 2.0 % placebo patient ) . The difference two treatment group number patient experience serious bleed event due great number drotrecogin alfa ( activate ) patient experience serious bleed event related procedure ( example , bleed result placement catheter nephrostomy tube ) . The number patient experience spontaneous serious bleed event similar two treatment group . The Regulatory authority approve use drotrecogin alfa ( activate ) severe sepsis patient high level disease severity risk death . Thus , regulatory authority request study evaluate drotrecogin alfa ( activate ) specific subpopulation patient severe sepsis low risk death .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Drotrecogin alfa activate</mesh_term>
	<mesh_term>Protein C</mesh_term>
	<criteria>Adult patient severe sepsis . Presence suspect proven infection . One sepsisassociated organ failure . Are indicated treatment drotrecogin alfa ( activate ) investigative site country . Are contraindicated treatment drotrecogin alfa ( activate ) applicable label investigative site country . Platelet count &lt; 30,000/mm3 . Are receive therapeutic heparin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>